Shanghai Sinotau Biotech Co. Ltd. has synthesized tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer, inflammation, atherosclerosis, fibrosis and keloid.

Blacksmith Medicines Inc. has disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, chronic obstructive pulmonary disease, atherosclerosis and Alzheimer’s disease, among others.

A Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. patent describes new ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer

Work at Beijing Tide Pharmaceutical Co. Ltd. has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to an EGFR (HER1; erbB1)-targeting moiety through a linker.

Mindset Pharma Inc. has patented new indoline derivatives acting as 5-HT1A receptor agonists and thus reported to be useful for the treatment of neurological and psychiatric disorders.

Sichuan Haisco Pharmaceutical Co. Ltd. has developed pyrazinone derivatives acting as protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors. They are reported to be useful for the treatment of cancer.

Sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers have been reported in a Vertex Pharmaceuticals Inc. patent as potentially useful for the treatment of pain, arrhythmia, Charcot-Marie-Tooth disease, cough, urinary incontinence and multiple sclerosis.

Debiopharm Research & Manufacturing SA has disclosed new antibody-drug conjugates consisting of monoclonal antibodies targeting CD37 covalently linked to a cytotoxic agent through a linker.

Work at Suzhou Genhouse Bio Co. Ltd. has led to the discovery of oxadiazole compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be potentially useful for the treatment of cancer, asthma, Alzheimer’s disease, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.

Humanwell Healthcare (Group) Co. Ltd. has identified new kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, autoimmune diseases and inflammatory bowel disease.